Livagen

Source-reported examples · not treatment recommendations

Amount

0.5–2 mg per day

Frequency

Once daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Livagen is identified as Lys-Glu-Asp-Ala, abbreviated KEDA, in original research on cultured lymphocytes. Its selected evidence spans rat liver explants and cells obtained from people with disease. The crucial distinction is where the intervention occurred: a peptide applied to a patient's cells in a laboratory is not a treatment administered to that patient. ^[1]
• A 2001 study reported growth of rat liver explants exposed to Livagen in organotypic culture. Other peptides were associated with other tissues in the same experiment. A related 2002 report compared synthetic peptides and tissue-derived preparations in rat explants across ages. Neither experiment establishes recovery from human liver disease. ^{[2] [3]}
• A 2017 study assessed DNA single-strand breaks, chromosome abnormalities and related genomic measures in lymphocyte cultures from people with ductal breast cancer. It discussed Livagen and cobalt as modifying agents and reported protective laboratory effects. This was not evidence of tumor shrinkage, cancer remission or improved survival after Livagen treatment. ^[4]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 11 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original identity and lymphocyte study
2. 2001 study
3. 2002 study
4. Original breast-cancer cell study
5. Biology Bulletin (Springer)Further reading · Listed in reference bibliography.
6. PubMedFurther reading · Listed in reference bibliography.
7. PubMedFurther reading · Listed in reference bibliography.
8. ResearchGate / Neuroendocrinology LettersFurther reading · Listed in reference bibliography.
9. CDCGeneral guidance · Listed in reference bibliography.
10. MedlinePlusGeneral guidance · Listed in reference bibliography.
11. PMCFurther reading · Listed in reference bibliography.
12. CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
13. Immunize.orgGeneral guidance · Listed in reference bibliography.
14. NCBI BookshelfFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.